Compare Kimberly Clark Corp (KMB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs TransMedics Group Inc — how do they compare? Kimberly Clark Corp trades at $97.99 (market cap $32.51B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Kimberly Clark Corp is far larger — about 11.9× TransMedics Group Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and TransMedics Group Inc for 24 Days on average.
| KMB | TMDX | |
|---|---|---|
Market Cap | $32.51B | $2.74B |
Volume | 6,139,913 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $150.42 |
52-Week Low | $93.05 | $61.99 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $38.07B | $3.13B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.59, up 1.15% on the day, but remains in a bearish technical trend. The stock has shown mixed earnings performance, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue declining to $16.45 billion in 2025. The company maintains a strong dividend history, recently declaring a $1.28 payout, while navigating its pending acquisition of Kenvue and executive transitions.
KMB offers a high dividend yield near 5%, supported by 54 consecutive years of increases, but faces risks from the Kenvue integration and cash flow pressures. Analyst consensus is a 'Hold' with a $117.25 price target, suggesting moderate upside. Key risks include execution of the large acquisition and sustaining dividend payouts amid fluctuating cash flows.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
